$MLRT
Metalert, Inc. Stock $mlrt

$mlrt Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000149315224021380 Filed on May 24, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue	$44.16K	$41.06K	$248.3K
YoY Change	-9.57%	20.62%	-25.78%
Cost Of Revenue	$14.93K	$67.55K	$226.9K
YoY Change	-65.52%	154.04%	19.57%
Gross Profit	$29.23K	-$26.49K	$21.44K
YoY Change	428.95%	-455.57%	-85.2%
Gross Profit Margin	66.19%	-64.52%	8.63%
Selling, General & Admin	$56.77K	$228.7K	$253.4K
YoY Change	-68.19%	-66.9%	1.87%
% of Gross Profit	194.21%		1182.1%
Research & Development			$18.86K
YoY Change			-0.54%
% of Gross Profit			87.97%
Depreciation & Amortization		$26.04K	$33.34K
YoY Change		-21.9%	0.0%
% of Gross Profit			155.52%
Operating Expenses	$116.8K	$237.1K	$898.4K
YoY Change	-37.47%	-66.1%	-40.71%
Operating Profit	-$87.59K	-$263.5K	-$876.9K
YoY Change	-51.68%	-61.91%	-36.01%
Interest Expense		-$830.00	-$255.7K
YoY Change		-98.5%	48.05%
% of Operating Profit
Other Income/Expense, Net	-$66.26K	-$39.69K	-$313.2K
YoY Change	142.79%	-60.64%	136.02%
Pretax Income		-$302.9K	-$1.190M
YoY Change		-61.17%	-20.82%
Income Tax
% Of Pretax Income
Net Earnings	-$153.9K	-$302.9K	-$1.190M
YoY Change	-26.24%	-61.17%	-20.82%
Net Earnings / Revenue	-348.39%	-737.63%	-479.26%
Basic Earnings Per Share	$0.00		-$0.05
Diluted Earnings Per Share	$0.00	-$0.01	-$0.05
COMMON SHARES
Basic Shares Outstanding	33.85M shares	32.12M shares	25.50M shares
Diluted Shares Outstanding	33.85M shares		25.50M shares

Balance Sheet

Concept	2024 Q2	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$30.23K	$69.09K	$69.09K
YoY Change	-33.92%	649.35%	649.35%
Cash & Equivalents	$29.58K	$68.44K	$68.44K
Short-Term Investments	$649.00	$650.00	$650.00
Other Short-Term Assets	$5.801K	$4.339K	$4.340K
YoY Change	21.61%	-46.07%	-46.09%
Inventory	$226.7K	$231.8K	$231.8K
Prepaid Expenses
Receivables		$17.41K	$17.41K
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$280.0K	$322.7K	$322.7K
YoY Change	133.53%	218.41%	218.42%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.65K	$25.78K	$25.78K
YoY Change	-70.2%	-56.39%	-56.39%
Goodwill
YoY Change
Intangibles	$234.0K	$261.8K
YoY Change	6972.91%	7812.97%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$246.6K	$287.5K	$287.6K
YoY Change	438.97%	360.59%	360.6%
TOTAL ASSETS
Total Short-Term Assets	$280.0K	$322.7K	$322.7K
Total Long-Term Assets	$246.6K	$287.5K	$287.6K
Total Assets	$526.6K	$610.2K	$610.2K
YoY Change	217.9%	272.61%	272.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$173.3K	$264.7K	$264.7K
YoY Change	4.88%	92.75%	92.74%
Accrued Expenses		$327.3K	$1.090M
YoY Change		-15.72%	23.0%
Deferred Revenue	$8.004K	$6.505K
YoY Change	22.2%	-49.38%
Short-Term Debt		$2.896M	$2.896M
YoY Change		31.12%	31.12%
Long-Term Debt Due		$115.0K	$115.0K
YoY Change		28.43%	28.43%
Total Short-Term Liabilities	$4.449M	$4.372M	$4.372M
YoY Change	19.14%	31.11%	31.11%
LONG-TERM LIABILITIES
Long-Term Debt		$137.0K	$137.0K
YoY Change		-3.57%	-3.57%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities		$137.0K	$137.0K
YoY Change		-3.57%	-3.57%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.449M	$4.372M	$4.372M
Total Long-Term Liabilities		$137.0K	$137.0K
Total Liabilities	$4.583M	$4.509M	$4.509M
YoY Change	18.32%	29.7%	29.7%
SHAREHOLDERS EQUITY
Retained Earnings	-$29.15M	-$28.75M
YoY Change	4.06%	4.32%
Common Stock	$3.385K	$3.245K
YoY Change	44.6%	88.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.057M	-$3.899M	-$3.899M
YoY Change
Total Liabilities & Shareholders Equity	$526.6K	$610.2K	$610.2K
YoY Change	217.9%	272.61%	272.62%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$153.9K	-$302.9K	-$1.190M
YoY Change	-26.24%	-61.17%	-20.82%
Depreciation, Depletion And Amortization		$26.04K	$33.34K
YoY Change		-21.9%	0.0%
Cash From Operating Activities		-$122.1K	-$417.2K
YoY Change		-75.92%	-17.7%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$0.00	$42.41K
YoY Change		-100.0%	-1381.27%
Cash From Investing Activities		$0.00	$42.41K
YoY Change		-100.0%	-1381.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		84.18K	$434.7K
YoY Change		-77.87%	14.27%
NET CHANGE
Cash From Operating Activities		-122.1K	-$417.2K
Cash From Investing Activities		0.000	$42.41K
Cash From Financing Activities		84.18K	$434.7K
Net Change In Cash		-37.90K	$59.91K
YoY Change		-70.8%	-146.15%
FREE CASH FLOW
Cash From Operating Activities		-$122.1K	-$417.2K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001375793
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023	MLRT	Care Edd Forgiveness CareEddForgiveness		usd
CY2022	MLRT	Gain On Settlement Of Debt GainOnSettlementOfDebt		usd
CY2023	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends		usd
CY2022	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends		usd
CY2023	MLRT	Redeemable Preferred Stock Dividends One RedeemablePreferredStockDividendsOne		usd
CY2022	MLRT	Redeemable Preferred Stock Dividends One RedeemablePreferredStockDividendsOne		usd
CY2022	MLRT	Stock Returned During Period Value Preferred A Stock To Treasury StockReturnedDuringPeriodValuePreferredAStockToTreasury		usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	MLRT	Gains Losses On Settlement Of Debt And Accrued Interest GainsLossesOnSettlementOfDebtAndAccruedInterest		usd
CY2023	MLRT	Interest And Financing Costs On Longterm Convertible Debt InterestAndFinancingCostsOnLongtermConvertibleDebt		usd
CY2023	MLRT	Grant From Care Loans GrantFromCareLoans		usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2023	us-gaap	Increase Decrease In Due To Officers And Stockholders Current IncreaseDecreaseInDueToOfficersAndStockholdersCurrent		usd
CY2023	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments		usd
CY2022	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets		usd
CY2023	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
CY2023	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt		usd
CY2022	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
CY2022	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt		usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2022	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	MLRT	Consolidation Of Debt ConsolidationOfDebt		usd
CY2022	us-gaap	Stock Issued1 StockIssued1		usd
CY2023	MLRT	Related Party Accrued Expenses To Convertible Debt Related Party RelatedPartyAccruedExpensesToConvertibleDebtRelatedParty		usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization		usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent		usd
CY2023Q4	MLRT	Paycheck Protection Program Loan Amount PaycheckProtectionProgramLoanAmount		usd
CY2022Q4	MLRT	Paycheck Protection Program Loan Amount PaycheckProtectionProgramLoanAmount		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022	MLRT	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2022	MLRT	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expired In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
CY2023	MLRT	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-53046
CY2023	dei	Entity Registrant Name EntityRegistrantName	MetAlert Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-0493446
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	117 W 9th Street
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1214
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Los Angeles
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90015
CY2023	dei	City Area Code CityAreaCode	213
CY2023	dei	Local Phone Number LocalPhoneNumber	489-3019
CY2023	dei	Security12g Title Security12gTitle	Common Stock, Par Value $0.0001
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	1407332	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	33845931	shares
CY2023	dei	Auditor Name AuditorName	M&K CPAS, PLLC
CY2023	dei	Auditor Location AuditorLocation	Houston, Texas
CY2023	dei	Auditor Firm AuditorFirmId	2738
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	68440	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8534	usd
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	17408	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	13959	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	231818	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	70112	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	649	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	683	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	4339	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	8045	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	322654	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	101333	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	261761	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3308	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25780	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	59121	usd
CY2023Q4	us-gaap	Assets Assets	610195	usd
CY2022Q4	us-gaap	Assets Assets	163762	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	264671	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	137315	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	327338	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	388414	usd
CY2023Q4	MLRT	Accrued Expenses Related Parties Current AccruedExpensesRelatedPartiesCurrent	762365	usd
CY2022Q4	MLRT	Accrued Expenses Related Parties Current AccruedExpensesRelatedPartiesCurrent	497551	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6505	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	12850	usd
CY2023Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	102040	usd
CY2022Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	81651	usd
CY2023Q4	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	12972	usd
CY2022Q4	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	7903	usd
CY2023Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1484142	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	843000	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	146195	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	149120	usd
CY2023Q4	MLRT	Notes Payable Related Parties NotesPayableRelatedParties	46500	usd
CY2022Q4	MLRT	Notes Payable Related Parties NotesPayableRelatedParties	10000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	248331	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	226892	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	189758	usd
CY2023	us-gaap	Gross Profit GrossProfit	21439	usd
CY2022	us-gaap	Gross Profit GrossProfit	144848	usd
CY2023	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	426758	usd
CY2022	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	509064	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	218180	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	757371	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	7778	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	22733	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	245652	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	226055	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	898368	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	1515223	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-876929	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-1370375	usd
CY2023	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	-34	usd
CY2022	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	-1782	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	102938	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	62067	usd
CY2022	MLRT	Care Edd Forgiveness CareEddForgiveness	102061	usd
CY2023	MLRT	Gain On Settlement Of Debt GainOnSettlementOfDebt	45405	usd
CY2023	MLRT	Interest Expense Income And Financing Costs InterestExpenseIncomeAndFinancingCosts	-255662	usd
CY2022	MLRT	Interest Expense Income And Financing Costs InterestExpenseIncomeAndFinancingCosts	-170924	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-313229	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-132712	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1190158	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1503087	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1190158	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1503087	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25499390	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25499390	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7197291	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7197291	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-3077195	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	621246	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	114062	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	180000	usd
CY2022	MLRT	Issuance Of Common Stock For Conversion Of Warrants IssuanceOfCommonStockForConversionOfWarrants	25001	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	129522	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1503087	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3312877	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3312877	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	56498	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	74211	usd
CY2023	MLRT	Issuance Of Preferred Stock For Financings IssuanceOfPreferredStockForFinancings	100000	usd
CY2023	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	247900	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	25552	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1190158	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-3898874	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-3898874	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1190158	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1503087	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	51045	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	33340	usd
CY2023	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	-34	usd
CY2022	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	-1782	usd
CY2023	MLRT	Fair Value Of Common Stock Issued For Services FairValueOfCommonStockIssuedForServices	56498	usd
CY2022	MLRT	Fair Value Of Common Stock Issued For Services FairValueOfCommonStockIssuedForServices	621246	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	16680	usd
CY2023	MLRT	Gains Losses On Settlement Of Debt And Accrued Interest GainsLossesOnSettlementOfDebtAndAccruedInterest	28725	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	102938	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	62067	usd
CY2022	MLRT	Interest And Financing Costs On Longterm Convertible Debt InterestAndFinancingCostsOnLongtermConvertibleDebt	116641	usd
CY2022	MLRT	Grant From Care Loans GrantFromCareLoans	67870	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	25552	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-417245	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-506950	usd
CY2022	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	3308	usd
CY2023	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	-42408	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3449	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	224	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-67629	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-28146	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-4549	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-47241	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	843	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	270	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	253200	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	29086	usd
CY2023	MLRT	Increase Decrease In Account Payable Related Parties IncreaseDecreaseInAccountPayableRelatedParties	267510	usd
CY2022	MLRT	Increase Decrease In Account Payable Related Parties IncreaseDecreaseInAccountPayableRelatedParties	139352	usd
CY2022	us-gaap	Increase Decrease In Due To Officers And Stockholders Current IncreaseDecreaseInDueToOfficersAndStockholdersCurrent	10000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-6345	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-24400	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	42408	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3308	usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	25000	usd
CY2022	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	180000	usd
CY2023	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	100000	usd
CY2023	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	345500	usd
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	145000	usd
CY2023	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	46881	usd
CY2022	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	144118	usd
CY2023	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	38500	usd
CY2023	us-gaap	Repayments Of Debt RepaymentsOfDebt	62646	usd
CY2022	us-gaap	Repayments Of Debt RepaymentsOfDebt	44201	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	5000	usd
CY2023	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	2000	usd
CY2023	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	26492	usd
CY2022	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	69467	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	434743	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	380450	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	59906	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-129808	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8534	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	138342	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	68440	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8534	usd
CY2023	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	74211	usd
CY2022	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	238124	usd
CY2023	MLRT	Consolidation Of Debt ConsolidationOfDebt	137500	usd
CY2023	MLRT	Transfer Of Convertible Related Party Debt TransferOfConvertibleRelatedPartyDebt	35000	usd
CY2022	MLRT	Transfer Of Convertible Related Party Debt TransferOfConvertibleRelatedPartyDebt	100000	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	100000	usd
CY2022	MLRT	Related Party Accrued Expenses To Convertible Debt Related Party RelatedPartyAccruedExpensesToConvertibleDebtRelatedParty	706248	usd
CY2023Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-65 reverse stock split
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1190158	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-28746629	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-3898874	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	248331	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	334606	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	248331	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	334606	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	12431	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	12431	usd
CY2023	us-gaap	Standard Product Warranty Description StandardProductWarrantyDescription	The Company’s warranty policy provides repair or replacement of products (excluding GPS Shoe devices) returned for defects within ninety days of purchase.
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84B_eus-gaap--UseOfEstimates_zRlPYp1QFWMg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86D_z6TZTfk0YJm3">Use of Estimates</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Material estimates relate to the assumptions made in determining reserves for uncollectible receivables, inventory reserves and returns, impairment analysis of long-term assets and deferred tax assets, accruals for potential liabilities and assumptions made in valuing the fair market value of equity transactions. Estimates are updated on an ongoing basis and are evaluated based on historical experience and current circumstances. Changes in facts and circumstances in the future may give rise to changes in these estimates which may cause actual results to differ from current estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q2	us-gaap	Line Of Credit Facility Current Borrowing Capacity LineOfCreditFacilityCurrentBorrowingCapacity	25000	usd
CY2023Q4	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	120000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18859	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18961	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zD8er4kXokq8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_865_z5Zikoj5Ziha">Concentrations</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We can rely on one or two manufacturers to supply us with our GPS SmartSole, in Germany and the U.S. Currently, for the Gun Tracker we have one supplier in China, but in order to have redundances we are looking for sources in the US and Mexico for manufacturing. However, the loss of any of these manufacturers could severely impede our ability to manufacture the GPS SmartSole and Gun Tracker, and thus as we increase production we are looking to augment and grow our vendors and supply chains accordingly.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, the Company had four customers representing approximately <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z7VE0JJvNLX7">29</span>%, <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zwQhq7mDKyA5">16</span>%, <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zP4gJqcTCXgl">16</span>% and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zvxnFdiWo5H7">15</span>% of sales and four customers representing approximately <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z94ljFCGwJWk">45</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zgSTvsZaKJ3k">14</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zJOiCENiYJqb">11</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zAHyBBXIDKbk">7</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of total accounts receivable, respectively. The Company had four customers representing approximately <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zzVbxVD53AGa">28</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zuTMUA2qR0Qe">21</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zdwgAMxDfCJ5">15</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% and <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zPlSslej9hx5">95</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of sales and three customers representing approximately <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zGJxIgW04SI5">50</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zXial24AZI2a">22</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, and <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zrufhMF8Nm6h" title="Concentration risk percentage">15</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of total accounts receivable, respectively, for the year ended December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	117670623	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	111615077	shares
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	integer
CY2023	MLRT	Investment Owned Description InvestmentOwnedDescription	The Company’s investments in marketable securities is comprised of shares of stock of two (2) entities with ownership percentages of less than 5%. The Company accounted for these investments pursuant to ASU 320, Investments – Debt and Equity Securities. As such, these investments were recorded at their market value as of December 31, 2019, with the change in fair value being reflected in the statement of operations.
CY2023	MLRT	Business Combination Consideration Transferred Including Equity Interest In Acquiree Held Prior To Convertible Notes BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToConvertibleNotes	200000	usd
CY2023	MLRT	Business Combination Consideration Transferred Including Equity Interest In Acquiree Held Prior To Common Stock BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCommonStock	347900	usd
CY2023	us-gaap	Business Combination Consideration Transferred Including Equity Interest In Acquiree Held Prior To Combination1 BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1	547900	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	42408	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory	229335	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	547900	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	146195	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	488254	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	454913	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25780	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	59121	usd
CY2023	us-gaap	Depreciation Depreciation	33341	usd
CY2022	us-gaap	Depreciation Depreciation	33340	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	17704	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	261761	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3308	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	149120	usd
CY2023Q4	us-gaap	Line Of Credit LineOfCredit	7000	usd
CY2022Q4	us-gaap	Line Of Credit LineOfCredit	7000	usd
CY2023Q4	us-gaap	Other Borrowings OtherBorrowings	95040	usd
CY2022Q4	us-gaap	Other Borrowings OtherBorrowings	74651	usd
CY2023Q4	us-gaap	Notes Payable NotesPayable	248235	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	230771	usd
CY2023Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	1483764	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	843000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	6788	usd
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	1484142	usd
CY2022Q4	us-gaap	Convertible Debt ConvertibleDebt	843000	usd
CY2023Q4	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	12972	usd
CY2022Q4	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	7903	usd
CY2023Q4	us-gaap	Other Loans Payable Long Term OtherLoansPayableLongTerm	137028	usd
CY2022Q4	us-gaap	Other Loans Payable Long Term OtherLoansPayableLongTerm	142097	usd
CY2023Q4	us-gaap	Other Loans Payable OtherLoansPayable	150000	usd
CY2022Q4	us-gaap	Other Loans Payable OtherLoansPayable	150000	usd
CY2022	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	68870	usd
CY2020Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	0	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	288764	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	423743	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	116236	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	87257	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-21000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-226000	usd
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-2664000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-2517000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2280000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2232000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4303602	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4066525	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4303602	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4066525	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	20490931	usd
CY2023	MLRT	Income Tax Expiration IncomeTaxExpiration	2028
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	478609	usd
CY2023	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	15266137	shares
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	940349	usd
CY2022	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	13723321	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	757693	shares
CY2022	MLRT	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice	0.16
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	153847	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	603846	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	400000	shares
CY2023	MLRT	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expired In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice	0.015
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	157692	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	846154	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023Q4	MLRT	Bonus Declared Or Accrued BonusDeclaredOrAccrued	0	usd
CY2022Q4	MLRT	Bonus Declared Or Accrued BonusDeclaredOrAccrued	0	usd

Files In Submission

Name	View Source	Status
0001493152-24-021380-index-headers.html	Edgar Link	pending
0001493152-24-021380-index.html	Edgar Link	pending
0001493152-24-021380.txt	Edgar Link	pending
0001493152-24-021380-xbrl.zip	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex3-2.htm	Edgar Link	pending
ex3-2_001.jpg	Edgar Link	pending
ex3-2_002.jpg	Edgar Link	pending
ex3-2_003.jpg	Edgar Link	pending
ex3-2_004.jpg	Edgar Link	pending
ex3-2_005.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mlrt-20231231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
mlrt-20231231_cal.xml	Edgar Link	unprocessable
mlrt-20231231_def.xml	Edgar Link	unprocessable
mlrt-20231231_lab.xml	Edgar Link	unprocessable
mlrt-20231231_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MLRT
Metalert, Inc. Stock $mlrt

2024 Q2 Form 10-K Financial Statement

#000149315224021380 Filed on May 24, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MLRT Metalert, Inc. Stock $mlrt

2024 Q2 Form 10-K Financial Statement

#000149315224021380 Filed on May 24, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MLRT
Metalert, Inc. Stock $mlrt